The tech firm reveals a focus on AI agents, Copilot expansion, Microsoft 365 updates, and global infrastructure investment.
From this month, the cost of a 10-minute, six-monthly Ocrevus (ocrelizumab) subcutaneous injection for relapsing-remitting multiple sclerosis (MS) will be slashed from more than $16,500 to $31.60 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback